ClinTec International Expands Further in MENA Region with Proposed Opening of Istanbul Office
News May 22, 2013
ClinTec International, a global CRO with a presence in over 40 countries worldwide, today announced its intention to formally open an office in Istanbul, Turkey. The office will not only provide ClinTec’s global team with access to a new patient population, but will also further consolidate the British CRO’s presence in the Middle East and North Africa (MENA) region. The office adds to the company’s current MENA region offices based in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut, Lebanon.
Speaking at the announcement of ClinTec’s new office, the company’s founder and CEO, Dr Rabinder Buttar commented; “The launch of this new office in Turkey confirms ClinTec International’s reputation as a truly global provider of quality assured clinical research services. It also reflects the growing significance of Turkey- and the wider MENA region- to the global clinical research market. We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole.”
The announcement ClinTec’s new Turkey office coincides with the company sponsoring the Partnerships in Clinical Trials Russia-CIS & MENA-Turkey conference held in Istanbul on 22-23rd May 2013. The conference aims to explore the challenges and opportunities facing companies when conducting clinical trials in the MENA region, and looks for the leading CROs within the region to provide solutions and advice on this complex market. As such, ClinTec’s Executive Vice-President- Global Clinical Development, Bindhya Cariappa, will be delivering a speech on Rare Disease Trials in the MENA region.
“Our sponsorship of the Partnerships in Clinical Trials Russia-CIS & MENA-Turkey Conference, coupled with the opening of the Turkey office, further emphasises our belief that ClinTec’s experienced local management team can easily negotiate the fast-moving and constantly evolving trial environment within the region,” added Dr Buttar.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE
Chemoradiotherapy Before Surgery Could Extend Lives of Pancreatic Cancer PatientsNews
Pancreatic cancer patients treated with chemotherapy and radiotherapy before surgery may live longer than those who have immediate surgery, according to unpublished clinical trial results.READ MORE